Neogenomics
NeoGenomics Q2 Revenues Grow 40 Percent
The company reported $121.7 million in total revenues for the quarter and said clinical services revenues rose 37 percent from the prior-year quarter.
In Brief This Week: Hologic, NeoGenomics, Natera, Saga Diagnostics, and More
News items for the in vitro diagnostics industry for the week of June 14, 2021.
NeoGenomics believes Inivata's assays will contribute meaningful revenues as early as 2023, driven by both firms' existing relationships with oncology and pathology groups.
Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC
As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status.
NeoGenomics Acquires Trapelo Health in $65M Deal
NeoGenomics will offer Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.
Oct 27, 2020
NeoGenomics Q3 Revenues Rise 20 Percent
Jul 28, 2020
NeoGenomics Q2 Revenues Fall 14 Percent
Apr 28, 2020